Clinical Trial Update: Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine

View source ↗

Summary

This clinical trial update highlights cardiotoxicity risks and potential risk factors in colorectal cancer patients treated with fluoropyrimidines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Capecitabine (capecitabine)

Snippet

Sponsor: Fondazione del Piemonte per l'Oncologia | Conditions: Colorectal Cancer | Status: UNKNOWN